Efficacy of Carrelizumab Combined with Albumin Paclitaxel and Cisplatin in the First-Line Treatment of Patients with Advanced Esophageal Cancer and Effects on Peripheral Blood PD-1 and PD-L1

HUANG Hui; LONG Yahui; TAN Lingxia; SHUI Mingcai

doi:10.14009/j.issn.1672-2124.2022.04.013

您当前的位置：

首页 >

文章列表页 >

Efficacy of Carrelizumab Combined with Albumin Paclitaxel and Cisplatin in the First-Line Treatment of Patients with Advanced Esophageal Cancer and Effects on Peripheral Blood PD-1 and PD-L1

更新时间：2022-10-08

- Efficacy of Carrelizumab Combined with Albumin Paclitaxel and Cisplatin in the First-Line Treatment of Patients with Advanced Esophageal Cancer and Effects on Peripheral Blood PD-1 and PD-L1
- Vol. 22, Issue 4, Pages: 444-448(2022)
- 作者机构：
  
  重庆市开州区人民医院肿瘤科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.04.013
  CLC： R735.1
- Published：2022，
扫描看全文
HUANG Hui, LONG Yahui, TAN Lingxia, et al. Efficacy of Carrelizumab Combined with Albumin Paclitaxel and Cisplatin in the First-Line Treatment of Patients with Advanced Esophageal Cancer and Effects on Peripheral Blood PD-1 and PD-L1. [J]. 22(4):444-448(2022)
DOI：

HUANG Hui, LONG Yahui, TAN Lingxia, et al. Efficacy of Carrelizumab Combined with Albumin Paclitaxel and Cisplatin in the First-Line Treatment of Patients with Advanced Esophageal Cancer and Effects on Peripheral Blood PD-1 and PD-L1. [J]. 22(4):444-448(2022) DOI： 10.14009/j.issn.1672-2124.2022.04.013.

摘要

目的：探讨卡瑞利珠单抗联合白蛋白紫杉醇和顺铂一线治疗晚期食管癌的疗效及对外周血程序性死亡受体1（PD-1）、程序性死亡受体配体1（PD-L1）的影响。方法：选取2019年7月至2020年10月该院收治的晚期食管癌患者80例作为研究对象进行前瞻性研究，按照随机数字表法按1∶1比例分为观察组、对照组，各40例。对照组患者采用白蛋白紫杉醇、顺铂治疗，观察组患者采用卡瑞利珠单抗联合白蛋白紫杉醇、顺铂治疗。比较两组患者的疗效，治疗前后肿瘤标志物[鳞状细胞癌相关抗原（SCC-Ag）、糖类抗原19-9（CA19-9）、细胞角质蛋白19片段抗原21-1（CYFRA21-1）和癌胚抗原（CEA）]、免疫功能指标[T细胞亚群（CD3

、CD4

/CD8

）、树状突细胞（DC）和DC/单核巨噬细胞（PBMC）]和血清PD-1、PD-L1水平，生活质量核心量表（QLQ-C30）评分及治疗期间不良反应发生情况，随访1年统计两组患者的生存情况。结果：观察组患者的疾病控制率为77.50%（31/40）

较对照组（55.00%

22/40）明显更高，差异有统计学意义（P

0.05）。治疗后，观察组患者血清CA19-9、CEA、CYFRA21-1和SCC-Ag水平较对照组明显更低，CD3

、CD4

/CD8

、DC和DC/PBMC水平较对照组明显更高，血清PD-1、PD-L1水平较对照组明显更低，QLQ-C30评分较对照组明显更低，差异均有统计学意义（P

0.05）。两组患者不良反应发生率的差异无统计学意义（P

0.05）。观察组患者的生存率为89.47%（34/38）

明显高于对照组的70.27%（26/37）

差异有统计学意义（P

0.05）。结论：卡瑞利珠单抗联合白蛋白紫杉醇和顺铂一线治疗晚期食管癌患者的效果显著，可有效调节血清PD-1、PD-L1的表达，提高免疫功能及生活质量，降低肿瘤标志物水平，且安全性高，生存期更长。

Abstract

OBJECTIVE: To probe into the efficacy of carrelizumab combined with albumin paclitaxel and cisplatin in the first-line treatment of patients with advanced esophageal cancer and effects on peripheral blood programmed death receptor 1（PD-1） and programmed death receptor ligand 1（PD-L1）. METHODS: Eighty patients with advanced esophageal cancer admitted to the hospital from Jul. 2019 to Oct. 2020 were extracted to be divided into the observation group and the control group at the ratio of 1∶1 according to the random number table method

with 40 cases in each group. The control group was treated with albumin paclitaxel and cisplatin

while the observation group received carrelizumab combined with albumin paclitaxel and cisplatin. The efficacy and levels of tumor markers[squamous cell carcinoma-associated antigen（SCC-Ag）

carbohydrate antigen 19-9（CA19-9）

cytokeratin 19 fragment antigen 21-1（CYFRA21-1）

carcinoembryonic antigen（CEA）]

immune function indicators[T cell subsets（CD3

CD4

/CD8

）

dendritic cells（DC）

DC/mononuclear macrophages（PBMC）]

serum PD-1

PD-L1

the core quality of life scale（QLQ-C30） score before and after treatment and the incidence of adverse reactions during treatment were compared between two groups. The survival of patients in both groups was counted at 1 year of follow-up. RESULTS: The disease control rate of the observation group was 77.50%（31/40）

significantly higher than 55.00%（22/40） of the control group

with statistically significant difference（P

0.05）. After treatment

the serum levels of CA19-9

CEA

CYFRA21-1 and SCC-Ag in the observation group were lower than those in the control group

the levels of CD3

CD4

/CD8

DC and DC/PBMC in the observation group were higher than those in the control group

the serum levels of PD-1 and PD-L1 in the observation group were lower than those in the control group

the QLQ-C30 score of the observation group was lower than that of the control group

with statistically significant differences（P

0.05）. There was no statistically significant difference in the incidence of adverse reactions between two groups（P

0.05）. The survival rate of the observation group was 89.47%（34/38）

higher than 70.27%（26/37） of the control group

with statistically significant difference（P

0.05）. CONCLUSIONS: The efficacy of carrelizumab combined with albumin paclitaxel and cisplatin in the first-line treatment of patients with advanced esophageal cancer is significant

which can effectively regulate the expression of serum PD-1 and PD-L1

improve the immune function and quality of life

reduce the levels of tumor markers

with higher safety and longer survival time.

关键词

卡瑞利珠单抗食管癌白蛋白紫杉醇晚期顺铂程序性死亡受体1程序性死亡受体配体1

Keywords

CarrelizumabEsophageal cancerAlbumin paclitaxelAdvancedCisplatinProgrammed death receptor 1Programmed death receptor ligand 1

references

查看原文

Views

143

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy of Internal Iliac Artery Transcatheter Arterial Chemoembolization with Gemcitabine Combined with Cisplatin/Lobaplatin in the Treatment of Muscle Invasive Bladder Urothelial Carcinoma

Economic Evaluation on Neoadjuvant Chemotherapy Combined with Surgery and Surgery Alone in the Treatment of Advanced Esophageal Cancer Based on Cost-Effectiveness Analysis

Efficacy of Carrelizumab Combined with Amlotinib in the Treatment of Advanced Gastric Cancer and Its Effect on Short-Term Prognosis

Mechanism of Picroside Ⅱ Inhibiting Proliferation,Invasion and Metastasis of Esophageal Cancer Cells Through MEK/ERK Pathway

Comparison of Clinical Efficacy of Simultaneous Proton and Heavy Ion Radiotherapy Between Cisplatin and Nedaplatin in the Treatment of Nasopharyngeal Malignant Tumor

Related Author

TANG Guanlin

LIN Wenjing

ZHOU Baicun

LIU Ying

ZENG Jianyong

DING Jin

ZHANG Yinying

CHEN Dandi

Related Institution

Dept. of Pharmacy, Chengdu Sixth People’s Hospital

Dept. of Urology, Chengdu Sixth People’s Hospital

College of Health Policy and Management, West China School of Public Health/West China Fourth Hospital, Sichuan University

Dept.of Oncology, Sichuan Cancer Hospital

Dept.of Oncology and Hematology,Nanchuan People’s Hospital,Chongqing Medical University

⁰